keyword
MENU ▼
Read by QxMD icon Read
search

Chronic graft versus host

keyword
https://www.readbyqxmd.com/read/28107317/photography-in-telemedicine-improving-diagnosis-of-chronic-graft-versus-host-disease%C3%A2
#1
Brianna Busby, Shannon Campbell, Rachel Cole, Charisse DeVries, Kamille Dobbins, Mary Beth Trimble, Mihkaila Wickline
BACKGROUND: The long-term follow-up (LTFU) team at the Seattle Cancer Care Alliance uses telemedicine to diagnose and treat post-transplantation complications in hematopoietic cell transplantation (HCT) survivors. Photos are often requested via the telemedicine service to aid in diagnosis, but they are typically of poor quality, making them unusable.
. OBJECTIVES: This project offered bachelor of science in nursing students, partnered with a comprehensive cancer center, the opportunity to participate in an evidence-based practice project to improve detection and management of chronic graft-versus-host disease (cGVHD) in patients after HCT...
February 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28107198/meta-analysis-of-the-actions-of-antithymocyte-globulin-in-patients-undergoing-allogeneic-hematopoietic-cell-transplantation
#2
Jiaojiao Yuan, Renzhi Pei, Wensi Su, Junjie Cao, Ying Lu
Graft-versus-host disease (GVHD) is a serious complication associated with allogeneic hematopoietic cell transplantation (allo-HCT). Antithymocyte globulin (ATG) is widely used prior to allo-HCT for GVHD prevention, though evidence of its efficacy remains unclear. We therefore identified nine randomized controlled trials (RCTs), enrolling 1089 patients (554 in the ATG group and 535 in the non-ATG group) to conduct a meta-analysis of the actions of ATG in allo-HCT. A relative risk or risk ratio (RR) and 95% confidence interval (CI) were calculated for each outcome...
January 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28104702/il-2-promotes-early-treg-reconstitution-after-allogeneic-hematopoietic-cell-transplantation
#3
Brian C Betts, Joseph Pidala, Jongphil Kim, Asmita Mishra, Taiga Nishihori, Lia Perez, Jose Leonel Ochoa-Bayona, Farhad Khimani, Kelly Walton, Ryan Bookout, Michael Nieder, Divis K Khaira, Marco Davila, Melissa Alsina, Teresa Field, Ernesto Ayala, Frederick L Locke, Marcie Riches, Mohamed Kharfan-Dabaja, Hugo Fernandez, Claudio Anasetti
Graft-versus-host disease remains a major cause of transplant-related mortality. Interleukin-2 plus sirolimus synergistically reduces acute graft-versus-host disease in rodents and promotes regulatory T-cells. This phase II trial tested the hypothesis that interleukin-2 would facilitate STAT5 phosphorylation in donor T-cells, expand regulatory T-cells, and ameliorate graft-versus-host disease. Between 4/16/2014-12/19/2015, 20 patients received interleukin-2 (200,000IU/m2 thrice weekly, days 0 to +90) with sirolimus (5-14ng/ml) and tacrolimus (3-7ng/ml) after HLA-matched related or unrelated allogeneic hematopoietic cell transplantation...
January 19, 2017: Haematologica
https://www.readbyqxmd.com/read/28103944/a-comparison-between-allogeneic-stem-cell-transplantation-from-unmanipulated-haploidentical-and-unrelated-donors-in-acute-leukemia
#4
Simona Piemontese, F Ciceri, M Labopin, W Arcese, S Kyrcz-Krzemien, S Santarone, H Huang, D Beelen, N C Gorin, C Craddock, Z Gulbas, A Bacigalupo, M Mohty, A Nagler
BACKGROUND: In the absence of a HLA-matched related or matched unrelated donor, allogeneic stem cell transplantation (allo-SCT) from mismatched unrelated donors or haploidentical donors are potential alternatives for patients with acute leukemia with an indication to allo-SCT. The objective of this study was to compare the outcome of allo-SCT from T cell-replete haploidentical (Haplo) versus matched (MUD 10/10) or mismatched unrelated donor at a single HLA-locus (MMUD 9/10) for patients with acute leukemia in remission...
January 19, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28102896/impact-of-pre-transplant-depression-on-outcomes-of-allogeneic-and-autologous-hematopoietic-stem-cell-transplantation
#5
Areej El-Jawahri, Yi-Bin Chen, Ruta Brazauskas, Naya He, Stephanie J Lee, Jennifer M Knight, Navneet Majhail, David Buchbinder, Raquel M Schears, Baldeep M Wirk, William A Wood, Ibrahim Ahmed, Mahmoud Aljurf, Jeff Szer, Sara M Beattie, Minoo Battiwalla, Christopher Dandoy, Miguel-Angel Diaz, Anita D'Souza, Cesar O Freytes, James Gajewski, Usama Gergis, Shahrukh K Hashmi, Ann Jakubowski, Rammurti T Kamble, Tamila Kindwall-Keller, Hilard M Lazarus, Adriana K Malone, David I Marks, Kenneth Meehan, Bipin N Savani, Richard F Olsson, David Rizzieri, Amir Steinberg, Dawn Speckhart, David Szwajcer, Helene Schoemans, Sachiko Seo, Celalettin Ustun, Yoshiko Atsuta, Jignesh Dalal, Carmem Sales-Bonfim, Nandita Khera, Theresa Hahn, Wael Saber
BACKGROUND: To evaluate the impact of depression before autologous and allogeneic hematopoietic cell transplantation (HCT) on clinical outcomes posttransplantation. METHODS: We analyzed data from the Center for International Blood and Marrow Transplant Research to compare outcomes after autologous (n = 3786) or allogeneic (n = 7433) HCT for adult patients with hematologic malignancies with an existing diagnosis of pre-HCT depression requiring treatment versus those without pre-HCT depression...
January 19, 2017: Cancer
https://www.readbyqxmd.com/read/28100265/allogeneic-stem-cell-transplantation-in-adult-patients-with-acute-myeloid-leukaemia-and-17p-abnormalities-in-first-complete-remission-a-study-from-the-acute-leukemia-working-party-alwp-of-the-european-society-for-blood-and-marrow-transplantation-ebmt
#6
Xavier Poiré, Myriam Labopin, Johan Maertens, Ibrahim Yakoub-Agha, Didier Blaise, Norbert Ifrah, Gérard Socié, Tobias Gedde-Dhal, Nicolaas Schaap, Jan J Cornelissen, Stéphane Vigouroux, Jaime Sanz, Lucienne Michaux, Jordi Esteve, Mohamad Mohty, Arnon Nagler
BACKGROUND: Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative option. METHODS: To address outcomes after allo-SCT in patients with abn(17p), we retrospectively analysed de novo or secondary AML undergoing SCT between 2000 and 2013 from the EBMT registry. RESULTS: One hundred thirty-nine patients with confirmed abn(17p) have been selected...
January 18, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28097534/successful-treatment-with-low-dose-nivolumab-in-refractory-hodgkin-lymphoma-after-allogeneic-stem-cell-transplantation
#7
Makoto Onizuka, Minoru Kojima, Keiko Matsui, Shinichiro Machida, Masako Toyosaki, Yasuyuki Aoyama, Hidetsugu Kawai, Jun Amaki, Ryujiro Hara, Akifumi Ichiki, Yoshiaki Ogawa, Hiroshi Kawada, Naoya Nakamura, Kiyoshi Ando
Previous studies have reported that an antibody that blocks programmed cell death 1 (PD-1) has therapeutic activity in patients with refractory/relapsed Hodgkin lymphoma (HL). However, the safety and efficacy of these agents in the post-allogeneic stem cell transplantation (allo-SCT) setting are not well known. Here, we describe a patient who was diagnosed as classical HL and treated with five regimens of chemotherapies with autologous SCT. Complete remission (CR) was not achieved following this initial treatment, so we performed allo-SCT from an HLA-matched sibling donor...
January 17, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28096088/how-i-treat-acquired-aplastic-anemia
#8
Andrea Bacigalupo
Acquired severe aplastic anemia (SAA) is a rare hematologic disease associated with significant morbidity and mortality. Immune destruction of hemopoietic stem cells, plays an important role in the pathogenesis, as shown by successful treatment with immunosuppressive agents (IST), leading to transfusion independence, or complete recovery of peripheral blood counts, in a proportion of patients. Growth factors, can be combined with IST, and may improve response rates, as recently shown with thrombopoietin analogs...
January 17, 2017: Blood
https://www.readbyqxmd.com/read/28094847/increased-regulatory-t-cell-graft-content-is-associated-with-improved-outcome-in-haematopoietic-stem-cell-transplantation-a-systematic-review
#9
Sheila A Fisher, Abigail Lamikanra, Carolyn Dorée, Betty Gration, Pat Tsang, Robert D Danby, David J Roberts
Allogeneic haematopoietic stem cell transplant (HSCT) recipients are at increased risk of morbidity and mortality, often due to the development of acute or chronic graft-versus-host disease (GVHD). Low numbers or proportions of regulatory T cells (Tregs) have been reported in patients who develop GVHD. We undertook a systematic review of studies that reported the Treg composition of HSCT grafts in patients with haematological malignancies. Fourteen eligible studies were identified, eight of which stratified patients by Tregs (absolute dose or ratio to CD3+ or CD4+ cells)...
January 17, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28091736/salvage-therapy-for-acute-chemorefractory-leukemia-by-allogeneic-stem-cell-transplantation-the-korean-experience
#10
Shin Hye Yoo, Youngil Koh, Dae-Young Kim, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, Sung-Soo Yoon, Seonyang Park, Sung-Kyu Park, Dae-Sik Hong, Hyeon Gyu Yi, Chul-Soo Kim, Ji Eun Jang, June-Won Cheong, Joonho Moon, Yoo Hong Min, Sang Kyun Sohn, Inho Kim
Little is known about the characteristics that make patients with acute leukemia suitable for undergoing salvage therapy by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we analyzed the clinical outcomes of 223 patients with acute leukemia who underwent allo-HSCT while not in complete remission (CR). The primary end points were overall survival (OS) and CR rate. CR was achieved in 79.8% of patients after allo-HSCT. Acute graft-versus-host disease (GVHD) was significantly associated with CR (P = 0...
January 16, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28087457/t-cell-replete-peripheral-blood-haploidentical-hematopoietic-cell-transplantation-with-post-transplant-cyclophosphamide-results-in-outcomes-similar-to-traditionally-matched-donors-in-active-disease-acute-myeloid-leukemia
#11
Joan How, Michael Slade, Khoan Vu, John F DiPersio, Peter Westervelt, Geoffrey L Uy, Camille N Abboud, Ravi Vij, Mark A Schroeder, Todd A Fehniger, Rizwan Romee
Outcomes for acute myeloid leukemia (AML) patients who fail to achieve complete remission remain poor. Hematopoietic cell transplantation (HCT) has been shown to induce long-term survival in AML patients with active disease. HCT is largely performed with HLA-matched unrelated or HLA-matched related donors. Recently, HCT with HLA-haploidentical related donors has been identified as a feasible option when HLA-matched donors are not immediately available. However, there is little data comparing outcomes of AML patients with active disease who receive haploidentical versus traditionally matched HCT...
January 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28073814/donor-derived-mycosis-fungoides-following-reduced-intensity-haematopoietic-stem-cell-transplantation-from-a-matched-unrelated-donor
#12
Francesca A M Kinsella, Mohammad Rasoul Amel Kashipaz, Julia Scarisbrick, Ram Malladi
A 46-year-old woman with a history of dasatinib-resistant chronic myeloid leukaemia, clonal evolution and monosomy 7 underwent reduced intensity conditioned in vivo T-cell-depleted allogeneic haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor. Following the transplantation, she developed recurrent cutaneous graft versus host disease (GvHD), which required treatment with systemic immunosuppression and electrocorporeal photophoresis. Concurrently, she developed a lichenoid rash with granulomatous features suggestive of cutaneous sarcoidosis...
January 10, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28073785/safety-and-efficacy-of-allogeneic-hematopoietic-stem-cell-transplant-after-pd-1-blockade-in-relapsed-refractory-lymphoma
#13
Reid W Merryman, Haesook T Kim, Pier Luigi Zinzani, Carmelo Carlo-Stella, Stephen M Ansell, Miguel-Angel Perales, Abraham Avigdor, Ahmad S Halwani, Roch Houot, Tony Marchand, Nathalie Dhedin, Willy Lescaut, Anne Thiebaut-Bertrand, Sylvie François, Aspasia Stamatoullas-Bastard, Pierre-Simon Rohrlich, Hélène Labussière Wallet, Luca Castagna, Armando Santoro, Veronika Bachanova, Scott C Bresler, Amitabh Srivastava, Harim Kim, Emily Pesek, Marie Chammas, Carol Reynolds, Vincent T Ho, Joseph H Antin, Jerome Ritz, Robert J Soiffer, Philippe Armand
Anti-PD-1 monoclonal antibodies are being increasingly tested in patients with advanced lymphoma. Following treatment, many of those patients are likely to be candidates for allogeneic hematopoietic stem cell transplant (HSCT). However, the safety and efficacy of HSCT may be affected by prior PD-1 blockade. We conducted an international retrospective analysis of 39 patients with lymphoma who received prior treatment with a PD-1 inhibitor, at a median time of 62 days (7-260) before HSCT. After a median follow-up of 12 months, the one-year cumulative incidences of grade 2-4 and grade 3-4 acute graft-versus-host disease (GVHD) were 44% and 23% respectively, while the one-year incidence of chronic GVHD was 41%...
January 10, 2017: Blood
https://www.readbyqxmd.com/read/28062916/low-dose-anti-thymocyte-globulin-reduce-severe-acute-and-chronic-graft-versus-host-disease-after-allogeneic-stem-cell-transplantation
#14
Osamu Imataki, Kensuke Matsumoto, Makiko Uemura
BACKGROUND: Anti-thymocyte globulin (ATG) administered at 5-10 mg/kg can prevent graft-versus-host disease (GVHD). We sought to investigate the potential for lower doses of ATG to decrease non-relapse mortality (NRM). METHODS: We consecutively compared the outcomes of patients with hematological diseases who received allogeneic stem cell transplants from allogeneic related or unrelated donors before February 2010 and were not administered ATG (reference arm), with those administered 2...
January 6, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28062216/post-transplant-cyclophosphamide-after-bone-marrow-transplantation-is-not-associated-with-an-increased-risk-of-donor-derived-malignancy
#15
Robbie G Majzner, Huzefa Mogri, Ravi Varadhan, Patrick Brown, Kenneth R Cooke, Javier Bolaños-Meade, Lode Swinnen, Jennifer Kanakry, Leo Luznik, Rick Jones, Ephraim Fuchs, Rich Ambinder, Yvette Kasamon, Heather J Symons
Post-transplant cyclophosphamide (PTCy) can be used for graft versus host disease (GVHD) prophylaxis alone or in combination with other agents and is associated with excellent rates of engraftment, acute and chronic GVHD, and an absence of post-transplant lymphoproliferative disease. No study has previously evaluated the risk for developing donor derived malignancy (DDM) in patients who receive PTCy. Giving chemotherapy in the immediate post-transplant period carries with it a theoretic risk of disturbing the graft at a time of increased hematopoietic stress and causing or accelerating the development of malignancy...
January 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28060366/oral-lichenoid-lesions-distinguishing-the-benign-from-the-deadly
#16
Susan Müller
Oral lichen planus is a chronic inflammatory disease of unknown etiology or pathogenesis with varied disease severity that waxes and wanes over a long period of time. Although a common oral mucosal disease, accurate diagnosis is often challenging due to the overlapping clinical and histopathological features of oral lichen planus and other mucosal diseases. Other immune-mediated mucocutaneous diseases can exhibit lichenoid features including mucous membrane pemphigoid, chronic graft-versus-host disease, and discoid lupus erythematosus...
January 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28060078/validation-of-international-chronic-ocular-graft-versus-host-disease-gvhd-group-diagnostic-criteria-as-a-chronic-ocular-gvhd-specific-metric
#17
Yuna Rapoport, Thomas Freeman, Tatsuki Koyama, Brian G Engelhardt, Madan Jagasia, Bipin N Savani, Uyen Tran, Adetola A Kassim
PURPOSE: To validate the International Chronic Ocular GVHD Consensus Group (ICCGVHD) diagnostic criteria for chronic ocular chronic graft-versus-host disease (GVHD), by comparing results with comprehensive ophthalmic evaluation after allogeneic hematopoietic stem cell transplantation. METHODS: A single-institution retrospective chart review was conducted on patients who underwent hematopoietic stem cell transplantation at Vanderbilt University Medical Center in Nashville, TN, from January 1, 2002, through April 17, 2014...
February 2017: Cornea
https://www.readbyqxmd.com/read/28052713/bronchiolitis-obliterans-syndrome-in-adults-after-allogeneic-stem-cell-transplantation-pathophysiology-diagnostics-and-treatment
#18
Ida Sofie Grønningsæter, Galina Tsykunova, Kyrre Lilleeng, Aymen Bushra Ahmed, Øystein Bruserud, Håkon Reikvam
Transplant-related complications are common after allogeneic hematopoietic stem cell transplantation (allo-HSCT), including graft versus host disease (GVHD). The lungs are frequently affected during the course of allo-HSCT, and among the non-infectious pulmonary complications bronchiolitis obliterans syndrome (BOS) is the most common and considered the only diagnostic manifestation of pulmonary GVHD. BOS is an irreversible obstructive disease that affects the terminal bronchioles, and it is associated with high morbidity and mortality rates...
January 4, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28039079/post-transplant-cyclophosphamide-and-tacrolimus-mycophenolate-mofetil-combination-prevents-graft-versus-host-disease-in-allogeneic-peripheral-blood-hematopoietic-cell-transplantation-from-hla-identical-donors
#19
Fabrizio Carnevale-Schianca, Daniela Caravelli, Susanna Gallo, Valentina Coha, Lorenzo D'Ambrosio, Elena Vassallo, Marco Fizzotti, Francesca Nesi, Luisa Gioeni, Massimo Berger, Alessandra Polo, Loretta Gammaitoni, Paolo Becco, Lidia Giraudo, Monica Mangioni, Dario Sangiolo, Giovanni Grignani, Delia Rota-Scalabrini, Antonino Sottile, Franca Fagioli, Massimo Aglietta
Allogeneic hematopoietic cell transplant (HCT) remains the only curative therapy for many hematologic malignancies but it is limited by high nonrelapse mortality (NRM), primarily from unpredictable control of graft-versus-host disease (GVHD). Recently, post-transplant cyclophosphamide demonstrated improved GVHD control in allogeneic bone marrow HCT. Here we explore cyclophosphamide in allogeneic peripheral blood stem cell transplantation (alloPBSCT). Patients with high-risk hematologic malignancies received alloPBSCT from HLA-matched unrelated/related donors...
December 27, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28027590/hepatitis-b-reactivation-in-occult-viral-carriers-undergoing-hematopoietic-stem-cell-transplantation-a-prospective-study
#20
Wai-Kay Seto, Thomas Sau-Yan Chan, Yu-Yan Hwang, Danny Ka-Ho Wong, James Fung, Kevin Sze-Hang Liu, Harinder Gill, Yuk-Fai Lam, Eric H Y Lau, Ka-Shing Cheung, Albert K W Lie, Ching-Lung Lai, Yok-Lam Kwong, Man-Fung Yuen
Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative, antibody to hepatitis B core antigen (anti-HBc) positive patients after allogeneic hematopoietic stem cell transplantation (HSCT) have not been prospectively studied. HBsAg-negative, anti-HBc positive patients with undetectable HBV DNA undergoing allogeneic HSCT were prospectively monitored every 4 weeks. The primary endpoint was HBV reactivation, defined as detectable HBV DNA (≥10 IU/mL). Secondary endpoints included overall survival, HBsAg-positivity, and changes in liver biochemistry and antibody to HBsAg levels...
December 27, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
keyword
keyword
15227
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"